Dr. Chakrabarti highlights 100% response with PD-1 blockade in dMMR rectal cancer and new chemoimmunotherapy for anal cancer.
2025 ASCO Annual Meeting
Stay up-to-date on the latest news, research updates, and presentations in GI cancer treatment from the ASCO 2025 Annual Meeting.
Advertisement
Dr. Chakrabarti shares BREAKWATER, CheckMate 8HW, and CHALLENGE results improving metastatic colorectal cancer outcomes.
Dr. Chakrabarti highlights ATOMIC as the new standard for stage III dMMR colon cancer and compares it to the NICHE approach.
Dr. Lieu lists and describes DESTINY-Gastric04, CHALLENGE, MATTERHORN, BREAKWATER, and ATOMIC.
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Findings from the CheckMate 8HW trial highlight a potential shift in treatment strategy for patients with MSI-H/dMMR mCRC.
The use of neoadjuvant/perioperative gemcitabine with cisplatin can boost OS and R0 resection rates in patients with BTC.
Dr. He shares her insights on the evolving role of single-agent vs combination IO in the neoadjuvant setting for aHCC.
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Dr. Mahalingam shares preliminary results from the randomized phase 2 study of elraglusib with gemcitabine/nab-paclitaxel.
A post hoc analysis of the NAPOLI 3 trial offers insight into prolonged survival in mPDAC.
A therapy has shown a statistically significant OS benefit in patients with unresectable locally advanced pancreatic cancer.
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Pembro plus lenvatinib with chemo may improve progression-free survival in patients when compared with the standard of care.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.